ErbB Surface Receptor Complexes as Biomarkers
    2.
    发明申请
    ErbB Surface Receptor Complexes as Biomarkers 审中-公开
    ErbB表面受体复合物作为生物标志物

    公开(公告)号:US20100291594A1

    公开(公告)日:2010-11-18

    申请号:US12689144

    申请日:2010-01-18

    IPC分类号: G01N33/574

    CPC分类号: G01N33/56905 G01N33/6893

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Methods for detecting receptor complexes comprising PI3K
    3.
    发明授权
    Methods for detecting receptor complexes comprising PI3K 有权
    用于检测包含PI3K的受体复合物的方法

    公开(公告)号:US07648828B2

    公开(公告)日:2010-01-19

    申请号:US11041073

    申请日:2005-01-21

    IPC分类号: G01N33/574

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法,包括存在或 不存在癌前状态,存在或不存在癌症状态,癌症预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Surface Receptor Complexes as Biomarkers
    4.
    发明申请
    Surface Receptor Complexes as Biomarkers 审中-公开
    表面受体复合物作为生物标志物

    公开(公告)号:US20090111127A1

    公开(公告)日:2009-04-30

    申请号:US11866293

    申请日:2007-10-02

    IPC分类号: G01N33/574 C12Q1/02 G01N33/53

    摘要: The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 本发明涉及包含细胞表面膜受体二聚体的患者样品中的新一类生物标志物。 在一个方面,本发明包括通过将这样的病症与在患者样品,特别是固定组织样品中直接测量的一种或多种细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面,本发明包括通过将样本细胞中的一种或多种细胞表面膜受体的二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症的状态的方法,包括存在或不存在 癌前状态,癌症状态的存在或不存在,癌症的预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Photoactivation device and method
    5.
    发明授权
    Photoactivation device and method 有权
    光活化装置及方法

    公开(公告)号:US07341362B2

    公开(公告)日:2008-03-11

    申请号:US10496683

    申请日:2002-12-18

    IPC分类号: F21V29/00

    CPC分类号: A61N5/062 A61N2005/0652

    摘要: A photoactivation apparatus (200) separately delivers light to a plurality of wells of a multiwell plate (110). The device-includes a plurality of light emitting diodes (210) attached to a first surface of a substrate (220) such that when the photoactivation apparatus is positioned on the multiwell plate each of the light emitting diodes delivers light to one corresponding well. The light emitting diodes (210) may extend at least partially into the wells of the multiwell plate. A heat sink (250) and fan may be provided on the device to dissipate heat generated by the light emitting diodes. The components are preferably enclosed in a conveniently-sized housing (270). The housing may include one or more grips and air vents. The apparatus includes an interlocking lip (230) defining a recess which is sized to receive at least a portion of the multiwell plate. A power supply connected to the apparatus and configured to provide an equal voltage across each of the light emitting diodes.

    摘要翻译: 光活化装置(200)分别将光传送到多孔板(110)的多个孔。 所述装置包括附接到基板(220)的第一表面的多个发光二极管(210),使得当所述光激活装置位于所述多孔板上时,每个发光二极管将光传送到一个对应的孔。 发光二极管(210)可以至少部分地延伸到多孔板的孔中。 可以在设备上提供散热器(250)和风扇以散发由发光二极管产生的热量。 部件优选地封闭在方便尺寸的壳体(270)中。 房屋可以包括一个或多个把手和通风口。 该装置包括限定凹部的互锁唇缘(230),凹部的尺寸设置成容纳多孔板的至少一部分。 连接到该装置并被配置成在每个发光二极管上提供相等电压的电源。

    METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS 审中-公开
    分析蛋白质的方法和组合物

    公开(公告)号:US20080311674A1

    公开(公告)日:2008-12-18

    申请号:US11837427

    申请日:2007-08-10

    IPC分类号: G01N27/26 G01N33/53

    摘要: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.

    摘要翻译: 公开了用于确定样品中一种或多种靶多肽已经经历了翻译后修饰的方法,组合物和试剂盒。 包含样品和包含切割诱导部分的第一试剂和用于靶多肽上的结合位点的第一结合剂的混合物经受各自结合部分的结合发生的条件。 结合位点是涉及靶多肽的翻译后修饰活性的结果。 该方法可用于确定靶多肽本身。 在另一个实施方案中,靶多肽的存在和/或量与试剂例如涉及靶多肽的翻译后修饰的酶的存在和/或量和/或活性有关。 第一结合剂和结合位点之间的相互作用使切割诱导部分紧密接近可切割部分,其可与多肽相关,并且仅在接近切割诱导部分时易于切割。 以这种方式,可以释放每个多肽的电泳标签。 分离释放的电泳标签,并且基于相应的电泳标签确定靶多肽的存在和/或量。

    ERBB HETERODIMERS AS BIOMARKERS
    8.
    发明申请
    ERBB HETERODIMERS AS BIOMARKERS 审中-公开
    ERBB HETERODIMERS作为生物标记

    公开(公告)号:US20080187948A1

    公开(公告)日:2008-08-07

    申请号:US11965659

    申请日:2007-12-27

    IPC分类号: C12Q1/02 G01N33/50

    摘要: A method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more heterodimers of ErbB, or Her, cell surface membrane receptors measured directly in a patient sample is described. The invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more heterodimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译: 描述了通过将这样的条件与直接在患者样品中测量的ErbB或Her的细胞表面膜受体的一个或多个异源二聚体的量相关联来确定疾病状态或健康状况的方法。 本发明包括通过将样品细胞中ErbB细胞表面膜受体的一个或多个异源二聚体的量的测量值与这样的状态相关联来确定来自个体的样本中癌症的状态的方法,包括存在或不存在前体 - 癌症状态,癌症状态的存在或不存在,癌症的预后或对治疗的反应性。 优选地,本发明的方法通过使用具有可释放分子标签的结合化合物来实现,所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后,分离标签被释放并与测定混合物分离,用于分析。

    Methods and compositions for analyzing proteins
    10.
    发明授权
    Methods and compositions for analyzing proteins 有权
    用于分析蛋白质的方法和组合物

    公开(公告)号:US07255999B2

    公开(公告)日:2007-08-14

    申请号:US10154042

    申请日:2002-05-21

    IPC分类号: G01N33/53 G01N33/533 C12Q1/42

    摘要: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.

    摘要翻译: 公开了用于确定样品中一种或多种靶多肽已经经历了翻译后修饰的方法,组合物和试剂盒。 包含样品和包含切割诱导部分的第一试剂和用于靶多肽上的结合位点的第一结合剂的混合物经受各自结合部分的结合发生的条件。 结合位点是涉及靶多肽的翻译后修饰活性的结果。 该方法可用于确定靶多肽本身。 在另一个实施方案中,靶多肽的存在和/或量与试剂例如涉及靶多肽的翻译后修饰的酶的存在和/或量和/或活性有关。 第一结合剂和结合位点之间的相互作用使切割诱导部分紧密接近可切割部分,其可与多肽相关,并且仅在接近切割诱导部分时易于切割。 以这种方式,可以释放每个多肽的电泳标签。 分离释放的电泳标签,并且基于相应的电泳标签确定靶多肽的存在和/或量。